uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Use of 5 alpha-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, UCR-Uppsala Clinical Research Center.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Urology.
Show others and affiliations
2013 (English)In: BMJ. British Medical Journal, ISSN 0959-8146, E-ISSN 0959-535X, Vol. 346, f3406- p.Article in journal (Refereed) Published
Abstract [en]

Objective To assess the association between 5 alpha-reductase inhibitor (5-ARI) use in men with lower urinary tract symptoms and prostate cancer risk. Design Nationwide, population based case-control study for men diagnosed with prostate cancer in 2007-09 within the Prostate Cancer data Base Sweden 2.0. Setting The National Prostate Cancer Register, National Patient Register, census, and Prescribed Drug Register in Sweden, from which we obtained data on 5-ARI use before date of prostate cancer diagnosis. Participants 26 735 cases and 133 671 matched controls; five controls per case were randomly selected from matched men in the background population. 7815 men (1499 cases and 6316 controls) had been exposed to 5-ARI. 412 men had been exposed to 5-ARI before the diagnosis of a cancer with Gleason score 8-10. Main outcome measures Risk of prostate cancer calculated as odds ratios and 95% confidence intervals by conditional logistic regression analyses. Results Risk of prostate cancer overall decreased with an increasing duration of exposure; men on 5-ARI treatment for more than three years had an odds ratio of 0.72 (95% confidence interval 0.59 to 0.89; P<0.001 for trend). The same pattern was seen for cancers with Gleason scores 2-6 and score 7 (both P<0.001 for trend). By contrast, the risk of tumours with Gleason scores 8-10 did not decrease with increasing exposure time to 5-ARI (for 0-1 year of exposure, odds ratio 0.96 (95% confidence interval 0.83 to 1.11); for 1-2 years, 1.07 (0.88 to 1.31); for 2-3 years, 0.96 (0.72 to 1.27); for >3 years, 1.23 (0.90 to 1.68); P=0.46 for trend). Conclusions Men treated with 5-ARI for lower urinary tract symptoms had a decreased risk of cancer with Gleason scores 2-7, and showed no evidence of an increased risk of cancer with Gleason scores 8-10 after up to four years' treatment.

Place, publisher, year, edition, pages
2013. Vol. 346, f3406- p.
National Category
Cancer and Oncology Urology and Nephrology
URN: urn:nbn:se:uu:diva-207267DOI: 10.1136/bmj.f3406ISI: 000320941900004PubMedID: 23778271OAI: oai:DiVA.org:uu-207267DiVA: diva2:647476
Available from: 2013-09-11 Created: 2013-09-11 Last updated: 2014-08-15Bibliographically approved

Open Access in DiVA

fulltext(533 kB)108 downloads
File information
File name FULLTEXT01.pdfFile size 533 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Garmo, HansBill-Axelson, AnnaHolmberg, Lars
By organisation
UCR-Uppsala Clinical Research CenterUrologyEndocrine Surgery
In the same journal
BMJ. British Medical Journal
Cancer and OncologyUrology and Nephrology

Search outside of DiVA

GoogleGoogle Scholar
Total: 108 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 304 hits
ReferencesLink to record
Permanent link

Direct link